Sign up
Pharma Capital
EPIC: ORGS
Market: NASDAQ
52-week High/Low: $9.25 / $3.80
Sector: Pharma & Biotech
Market Cap: $65.75M

Orgenesis is a development stage company with a novel therapeutic approach in the treatment of diabetes by correcting malfunctioning organs with new functional tissues created from the patient’s own existing organs. Orgenesis employs a molecular and cellular approach directed at converting liver cells into functional insulin-producing cells as a treatment for diabetes.

Orgenesis

www.orgenesis.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Orgenesis

View full ORGS profile View Profile
View All

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.